Bringing treatments to life

Clinical Redefined

​​80% of life-saving innovations come from emerging biotechs, yet getting them to patients is where the system breaks down. Reaching human PoC remains painfully slow, capital-intensive, and high-risk. Investors increasingly want more human patient data before investing. And the regulatory and competitive landscape increasingly demands companies to move even faster, show more evidence, and stay more flexible.

More requirements. Fewer funds. Less time.

This is where Vivara Clinical comes in: to bridge the growing gap between concept and clinical proof with high-quality, faster, and more budget sensible preclinical and clinical solutions, so we can continue to see the best innovations help the most patients.

Tony Xu, PhD

Managing Director, Vivara